Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 1/20 | 0.52 |
| ▸ | MMP9 | P14780 | 1/20 | 0.52 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 3/20 | 0.51 |
| ▸ | TYR | P14679 | 1/20 | 0.51 |
| ▸ | DAO | P14920 | 1/20 | 0.51 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.51 |
| ▸ | MAOA | P21397 | 3/20 | 0.51 |
| ▸ | MAOB | P27338 | 5/20 | 0.50 |
| ▸ | CA12 | O43570 | 2/20 | 0.47 |
| ▸ | CA9 | Q16790 | 2/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA3 | P07451 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | CA4 | P22748 | 1/20 | 0.47 |
| ▸ | CA6 | P23280 | 1/20 | 0.47 |
| ▸ | CA5A | P35218 | 1/20 | 0.47 |
| ▸ | CA7 | P43166 | 1/20 | 0.47 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9233570 | 0.84 | MAOA (0.51) | MMP2MMP9ADAM17HPGDTYR | |
| SCHEMBL7142290 | 0.84 | POLB (0.51) | MMP2MMP9ADAM17HPGDTYR | |
| SCHEMBL8366995 | 0.82 | MAOB (0.57) | MMP2MMP9ADAM17HPGDTYR | |
| SCHEMBL28468188 | 0.82 | MMP2 (0.50) | MMP2MMP9ADAM17HPGDTYR | |
| SCHEMBL28468189 | 0.82 | MMP2 (0.50) | MMP2MMP9ADAM17HPGDTYR | |
| SCHEMBL3267547 | 0.81 | MAOA (0.54) | MMP2MMP9ADAM17HPGDTYR | |
| SCHEMBL7140695 | 0.81 | MAOB (0.50) | MMP2MMP9ADAM17HPGDTYR | |
| SCHEMBL15558092 | 0.80 | VKORC1 (0.54) | MMP2MMP9ADAM17HPGDTYR | |
| SCHEMBL30865952 | 0.78 | GAPDH (0.50) | MMP2MMP9ADAM17HPGDTYR | |
| SCHEMBL3009674 | 0.78 | HPGD (0.59) | MMP2MMP9ADAM17HPGDTYR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1032265-B1 | NEW PSORALENS FOR PATHOGEN INACTIVATION | CERUS CORP (US) | 2003-10-29 | — | — | EP | disclosed |
| US-20030082510-A1 | Psoralens for pathogen inactivation | CERUS CORPORATION (US) | 2003-05-01 | — | — | US | disclosed |
| US-6455286-B1 | MIXING PSORALEN COMPOUND OF DEFINED STRUCTURE WITH BIOLOGICAL COMPOSITION SUCH AS BLOOD OR PLATELETS, THEN PHOTOACTIVATING COMPOUND TO DEACTIVATE PATHOGEN | CERUS CORPORATION | 2002-09-24 | — | — | US | disclosed |
| EP-1032265-A4 | NEW PSORALENS FOR PATHOGEN INACTIVATION | CERUS CORP (US) | 2001-05-30 | — | — | EP | disclosed |
| US-6133460-A | HAVE PRIMARY AMINO SUBSTITUTIONS ON THE 3-, 4-, 5-, AND 8-POSITIONS OF THE PSORALEN WHICH PERMIT BINDING TO NUCLEIC ACID OF PATHOGENS; CONDITIONS THAT PHOTOACTIVATE THESE PSORALENS RESULT IN INACTIVATION OF PATHOGENS WHICH CONTAIN NUCLEIC ACID | CERUS CORPORATION (US) | 2000-10-17 | — | — | US | disclosed |
| EP-1032265-A1 | NEW PSORALENS FOR PATHOGEN INACTIVATION | Cerus Corporation (US) | 2000-09-06 | — | — | EP | disclosed |
| EP-0736529-B1 | Improved reagents for a cannabinoid immunoassay | HOFFMANN LA ROCHE (CH) | 2000-07-05 | — | — | EP | disclosed |
| WO-1999026476-A1 | NEW PSORALENS FOR PATHOGEN INACTIVATION | CERUS CORPORATION (US) | 1999-06-03 | — | — | WO | disclosed |
| US-5817766-A | CONTAINING A BENZPYRAN COMPOUND | ROCHE DIAGNOSTIC SYSTEMS, INC. (US) | 1998-10-06 | — | — | US | disclosed |
| EP-0736529-A1 | Improved reagents for a cannabinoid immunoassay | F. HOFFMANN-LA ROCHE AG (CH) | 1996-10-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030082510-A1 | Psoralens for pathogen inactivation | BPGM, XPA, RAD50 | MMP2 4024/4885MMP9 4308/4885ADAM17 3822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.